
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : miCAR19
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Antion Develops Safety-Enhanced Off-The-Shelf CAR T-Cells For Autoimmune Disease
Details : miCAR19, is an anti-CD19 CAR T-cell &gene therapy candidate, which is currently being evaluated for the treatment of B-cell driven autoimmune diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : miCAR19
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : miCAR7
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Antion Shares Data Validating Its Technology Platform Through Milestone Achievements
Details : miCAR7 is an allogeneic anti-CD7 chimeric antigen receptor (CAR7) T-cell product with simultaneous modulation of six molecules. It is being evaluated for the treatment of cancer.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : miCAR7
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Allogene Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of this agreement, Antion will exclusively collaborate with Allogene on oncology products for a defined period. Allogene will also have exclusive worldwide rights to commercialize products incorporating Antion technology developed during the coll...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Allogene Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
